Literature DB >> 7485055

Recall accuracy for prescription medications: self-report compared with database information.

S L West1, D A Savitz, G Koch, B L Strom, H A Guess, A Hartzema.   

Abstract

A methodological study was performed in 1992 to evaluate the accuracy of self-reported use of nonsteroidal antiinflammatory drugs (NSAIDs) and noncontraceptive estrogens that had been dispensed during the previous 12 years. A sample of 560 individuals dispensed NSAIDs or estrogens, and 140 individuals without NSAID/estrogen dispensations were selected from the Group Health Cooperative pharmacy database. Demographic, behavioral, and drug information was ascertained by telephone interview for 356 persons with and 98 persons without NSAID/estrogen dispensations. Of those with only a single NSAID dispensation, 41% (95% confidence interval (CI) 32-50%) were able to recall any NSAID use compared with 85% (95% CI 76-94%) for those with multiple NSAID dispensations. Thirty percent (95% CI 24-36%) recalled the NSAID name, and 15% (95% CI 10-20%) recalled both the name and dose. For estrogens, 78% (95% CI 70-86%) recalled the name, but only 26% (95% CI 17-34%) recalled the name and dose. Age, but not sex, appeared to influence recall accuracy: Persons 50-65 years of age recalled the NSAID name more accurately than those aged 66-80 (odds ratio (OR) = 1.8, 95% confidence interval (CI) 1.0-3.4). A similar advantage was noted for 50- to 65-year-old women in recalling the estrogen name (OR = 1.5, 95% CI 0.6-3.9). Drug name was recalled more frequently for exposures stopped 2-3 years prior to interview than for those stopped 7-11 years prior (OR = 3.0, 95% CI 1.6-5.7, and OR = 2.4, 95% CI 0.9-6.7, for NSAIDs and estrogens, respectively). Specificity was consistently high, ranging from 92% to 100%. This study suggests significant underascertainment of self-reported prescription drug exposure but little evidence that exposures are overreported.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485055     DOI: 10.1093/oxfordjournals.aje.a117563

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  110 in total

1.  Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis.

Authors:  Vivian K Kawai; Carlos G Grijalva; Patrick G Arbogast; Jeffrey R Curtis; Daniel H Solomon; Elizabeth Delzell; Lang Chen; Rita Ouellet-Hellstrom; Lisa Herrinton; Liyan Liu; Edward F Mitchel; C Michael Stein; Marie R Griffin
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-10       Impact factor: 4.794

2.  Increasing pregnancy-related use of prescribed opioid analgesics.

Authors:  Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper
Journal:  Ann Epidemiol       Date:  2013-08       Impact factor: 3.797

3.  Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life.

Authors:  Pauline M Maki; Lorraine Dennerstein; Margaret Clark; Janet Guthrie; Pamela LaMontagne; Deanne Fornelli; Deborah Little; Victor W Henderson; Susan M Resnick
Journal:  Brain Res       Date:  2010-11-13       Impact factor: 3.252

4.  Opioid Analgesics and the Risk of Serious Infections Among Patients With Rheumatoid Arthritis: A Self-Controlled Case Series Study.

Authors:  Andrew D Wiese; Marie R Griffin; C Michael Stein; Edward F Mitchel; Carlos G Grijalva
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

5.  Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.

Authors:  Anna Citarella; Marie Linder; Helle Kieler; Ingegärd Anveden Berglind; Anders Sundström; Björn Wettermark; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2015-12-16       Impact factor: 2.953

6.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

7.  Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.

Authors:  Sylvie Perreault; Lucie Blais; Alice Dragomir; Marie-Hèlène Bouchard; Lyne Lalonde; Claudine Laurier; Johanne Collin
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

8.  Recall of drug utilization depends on subtle structural questionnaire characteristics.

Authors:  Nuno Lunet; Joana Bastos; Florência Cumaio; Paula Silva; Eunice Dias; Henrique Barros
Journal:  Pharm World Sci       Date:  2007-09-19

9.  Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.

Authors:  J Blouin; A Dragomir; M Fredette; L-G Ste-Marie; J C Fernandes; S Perreault
Journal:  Osteoporos Int       Date:  2008-12-24       Impact factor: 4.507

10.  Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study.

Authors:  Lillian R Meacham; Eric J Chow; Kirsten K Ness; Kala Y Kamdar; Yan Chen; Yutaka Yasui; Kevin C Oeffinger; Charles A Sklar; Leslie L Robison; Ann C Mertens
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.